Premium
Cell therapy products: focus on issues with manufacturing and quality control of chimeric antigen receptor T‐cell therapies
Author(s) -
Eyles Jim E,
Vessillier Sandrine,
Jones Anika,
Stacey Glyn,
Schneider Christian K,
Price Jack
Publication year - 2019
Publication title -
journal of chemical technology and biotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.64
H-Index - 117
eISSN - 1097-4660
pISSN - 0268-2575
DOI - 10.1002/jctb.5829
Subject(s) - chimeric antigen receptor , medicine , therapeutic modalities , modalities , quality (philosophy) , immunotherapy , immunology , immune system , social science , philosophy , sociology , epistemology
Recent accelerated approvals of Chimeric Antigen Receptor T‐cell (CAR‐T) therapies targeting refractory haematological malignancies underscore the potential for this novel technology platform to provide new therapeutic options for oncology areas with high unmet medical needs. However, these powerful ‘living drugs’ are markedly different to conventional small molecule and biologic therapies on several levels. The highly complex nature and varied composition of CAR‐T based products still requires considerable investigation to resolve the best approaches to ensure reproducible and cost‐effective manufacture, clinical development, and application. This review will focus on key issues for manufacturing and quality control of these exciting new therapeutic modalities, preceded by a brief description of CAR principals and clinical development considerations. © 2018 The Authors. Journal of Chemical Technology & Biotechnology published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.